Objective： Mahuang-Shigao herb-pair is a famous formula composed of Ephedra and Gypsum. The herb-pair is frequently used for treating cold symptoms and bronchial asthma in the clinical practice of Chinese medicine ...Objective： Mahuang-Shigao herb-pair is a famous formula composed of Ephedra and Gypsum. The herb-pair is frequently used for treating cold symptoms and bronchial asthma in the clinical practice of Chinese medicine （CM）. In the present study, we evaluated evidence for the benefit of combined use of Ephedra and Gypsum by analyzing the antipyretic and anti-asthmatic activities of Ephedra-Gypsum. Methods： The antipyretic effects of Ephedra-Gypsum were evaluated in yeast-induced hyperthermia test. Thirty male Wistar rats were randomly divided into 5 groups, including control group, standard aspirin group, and 3 Ephedra- Gypsum groups of different doses （6, 12, 24 g/kg）. Ephedra-Gypsum extract and asprin were administered orally 6 h after the injection of yeast solution and body temperature was measured every 1 h for 8 h. The anti- asthmatic effects of Ephedra-Gypsum were evaluated using an ovalbumin （OVA）-induced asthmatic rat model. Thirty-six male SD rats were randomly divided into 6 groups. Rats were alternately sensitized and OVA＋Al（OH）3 challenged by exposure to mists of ovalbumin. Ephedra-Gypsum extracts （6, 12, 24 g/kg） or dexamethasone were administered 45 min prior to the allergen challenge for 8 days. Latent period and the weight of wet to dry ratio of lung were determined. In addition, the eosinophils in blood and white blood cell （WBC） were counted by an YZ-Hemavet Analyzer. Results： The Ephedra-Gypsum extracts at test dose （6, 12, 24 g/kg） significantly and dose-dependently attenuated yeast-induced fever in rats. The Ephedra-Gypsum extracts also prolonged the latent period, reduced OVA-induced increases in eosinophils and WBC, and decreased the wet and dry weight ratio of the lungs in the anti-asthmatic test. Conclusions： These findings indicate that the Ephedra-Gypsum extract has antipyretic and anti-asthmatic properties. Hence, the results support additional scientific evidence in prescriptions.展开更多
Objective:The objective of this study was to investigate the potential mechanisms of ephedra-gypsum in the treatment ofrespiratory diseases(RDs)using network pharmacology and molecular docking techniques.Materials and...Objective:The objective of this study was to investigate the potential mechanisms of ephedra-gypsum in the treatment ofrespiratory diseases(RDs)using network pharmacology and molecular docking techniques.Materials and Methods:The TCMSP and UniProt databases were used to mine the active components and targets of ephedra-gypsum,and the targets of RD were screened using the Online Mendelian Inheritance in Man(OMIM)and GeneCards databases.The protein-protein interaction network graph was created using the drug-disease intersection targets in the STRING database.The network diagram was analyzed using Cytoscape 3.9.1's topology function.The gene ontology(GO)and KEGG enrichment analyses were performed using the DAVID platform.Molecular docking bioactivity validation of the main active components and core targets was performed using AutoDock and PyMOL software.Results:Twenty-four compounds were screened,and 113 drug-disease targets overlapped.In total,358 biological processes,67 molecular functions,38 cellular components of GO,and 139 pathways were identified.Molecular docking analysis demonstrated the strong binding ability of tumor protein 53(TP53)-luteolin.Conclusion:The core components of ephedra-gypsum,such as quercetin,luteolin,kaempferol,and CaSO_(4)·2H_(2)O,act on key targets,such as tumor necrosis factor(TNF),interleukin-6(IL-6),TP53,and IL-1β through cytokine-mediated signaling pathways,infiammatory responses,cell proliferation,and apoptosis.This could be useful for the treatment of RD.展开更多
基金Supported by the National Natural Science Foundation of China(No.81030066)
文摘Objective： Mahuang-Shigao herb-pair is a famous formula composed of Ephedra and Gypsum. The herb-pair is frequently used for treating cold symptoms and bronchial asthma in the clinical practice of Chinese medicine （CM）. In the present study, we evaluated evidence for the benefit of combined use of Ephedra and Gypsum by analyzing the antipyretic and anti-asthmatic activities of Ephedra-Gypsum. Methods： The antipyretic effects of Ephedra-Gypsum were evaluated in yeast-induced hyperthermia test. Thirty male Wistar rats were randomly divided into 5 groups, including control group, standard aspirin group, and 3 Ephedra- Gypsum groups of different doses （6, 12, 24 g/kg）. Ephedra-Gypsum extract and asprin were administered orally 6 h after the injection of yeast solution and body temperature was measured every 1 h for 8 h. The anti- asthmatic effects of Ephedra-Gypsum were evaluated using an ovalbumin （OVA）-induced asthmatic rat model. Thirty-six male SD rats were randomly divided into 6 groups. Rats were alternately sensitized and OVA＋Al（OH）3 challenged by exposure to mists of ovalbumin. Ephedra-Gypsum extracts （6, 12, 24 g/kg） or dexamethasone were administered 45 min prior to the allergen challenge for 8 days. Latent period and the weight of wet to dry ratio of lung were determined. In addition, the eosinophils in blood and white blood cell （WBC） were counted by an YZ-Hemavet Analyzer. Results： The Ephedra-Gypsum extracts at test dose （6, 12, 24 g/kg） significantly and dose-dependently attenuated yeast-induced fever in rats. The Ephedra-Gypsum extracts also prolonged the latent period, reduced OVA-induced increases in eosinophils and WBC, and decreased the wet and dry weight ratio of the lungs in the anti-asthmatic test. Conclusions： These findings indicate that the Ephedra-Gypsum extract has antipyretic and anti-asthmatic properties. Hence, the results support additional scientific evidence in prescriptions.
基金supported by Grants from the National Natural Science Foundation of China(grant no.U20A20404)National College Students'Innovation and Entrepreneurship Training Program(202210752014).
文摘Objective:The objective of this study was to investigate the potential mechanisms of ephedra-gypsum in the treatment ofrespiratory diseases(RDs)using network pharmacology and molecular docking techniques.Materials and Methods:The TCMSP and UniProt databases were used to mine the active components and targets of ephedra-gypsum,and the targets of RD were screened using the Online Mendelian Inheritance in Man(OMIM)and GeneCards databases.The protein-protein interaction network graph was created using the drug-disease intersection targets in the STRING database.The network diagram was analyzed using Cytoscape 3.9.1's topology function.The gene ontology(GO)and KEGG enrichment analyses were performed using the DAVID platform.Molecular docking bioactivity validation of the main active components and core targets was performed using AutoDock and PyMOL software.Results:Twenty-four compounds were screened,and 113 drug-disease targets overlapped.In total,358 biological processes,67 molecular functions,38 cellular components of GO,and 139 pathways were identified.Molecular docking analysis demonstrated the strong binding ability of tumor protein 53(TP53)-luteolin.Conclusion:The core components of ephedra-gypsum,such as quercetin,luteolin,kaempferol,and CaSO_(4)·2H_(2)O,act on key targets,such as tumor necrosis factor(TNF),interleukin-6(IL-6),TP53,and IL-1β through cytokine-mediated signaling pathways,infiammatory responses,cell proliferation,and apoptosis.This could be useful for the treatment of RD.
